Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Matt Stevenson,1* Rachel Archer,1 Jon Tosh,1 Emma Simpson,1 Emma Everson-Hock,1 John Stevens,1 Monica Hernandez-Alava,1 Suzy Paisley,1 Kath Dickinson,1 David Scott,2 Adam Young3 and Allan Wailoo1

1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK
3Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK

*Corresponding author

Declared competing interests of authors: David Scott has received honoraria within the last 3 years for providing advice to Merck Sharp & Dohme Corp., UCB Pharma and Bristol-Myers Squibb: these values were less than £1000. Additionally, David Scott has received grants from Arthritis Research UK and the National Institute for Health Research in connection with rheumatoid arthritis.

Published April 2016
DOI: 10.3310/hta20350
Plain English summary

Biologic DMARDs for the treatment of rheumatoid arthritis
Health Technology Assessment 2016; Vol. 20: No. 35
DOI: 10.3310/hta20350

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Review question

The clinical effectiveness and cost-effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) compared with conventional disease-modifying antirheumatic drugs (cDMARDs) in individuals with rheumatoid arthritis was assessed.

Background

Rheumatoid arthritis is associated with significant morbidity. bDMARDs are more efficacious than cDMARDs, but are considerably more expensive.

Work undertaken

A systematic review of randomised controlled trials of efficacy was undertaken. Network meta-analyses were undertaken to ensure coherent results regarding efficacy. Interrogation of an observational database was performed to provide data on disease progression when treated with cDMARDs. A mathematical model was constructed to estimate the incremental cost per quality-adjusted life-year (QALY).

Key results

Fifty-two clinical trials provided data on American College of Rheumatology and/or European League Against Rheumatism responses for bDMARDs (38 in the main analyses and 14 for sensitivity analyses). These data were synthesised to produce coherent results. bDMARDs were shown to be more effective than cDMARDs. The interrogation of the database indicated that historical assumptions regarding disease progression while on cDMARDs were far too pessimistic. Results from the cost-effectiveness analyses indicated typical cost per QALY of ≥ £40,000. These are higher than values reported by the National Institute for Health and Care Excellence as thresholds for an intervention to be considered cost-effective.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 11/74/01. The protocol was agreed in November 2012. The assessment report began editorial review in October 2013 and was accepted for publication in January 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk